EQUITY RESEARCH MEMO

Plasma Surgical

Generated 5/10/2026

Executive Summary

Conviction (model self-assessment)55/100

Plasma Surgical is a French medical device company pioneering pure-plasma technology for surgical applications. Its flagship product, the PlasmaJet Ultra, is an all-in-one surgical tool that uses a controlled stream of pure plasma to cut, dissect, vaporize, coagulate, and surface seal tissue. The technology aims to improve patient care by offering versatility, precision, and safety through a single handheld device. Founded in 2007 and headquartered in Paris, the company is privately held and has not disclosed funding or valuation details. Despite limited public visibility, its innovative approach addresses critical needs in minimally invasive and open surgery, potentially disrupting traditional electrosurgical and ultrasonic devices. The company's product seems commercially available, but adoption likely depends on clinical validation, regulatory clearances, and market penetration. With a focus on safety and ease of use, Plasma Surgical targets surgeons seeking efficient, multi-functional instrumentation.

Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)